Percutaneous Two-Dimensional Shear Wave Elastography for Diagnosis of Pancreatic Tumor.
2D-shear wave elastography
pancreatic cancer
tumor-forming pancreatitis
ultrasonography
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
11 Mar 2021
11 Mar 2021
Historique:
received:
29
01
2021
revised:
03
03
2021
accepted:
05
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
To investigate the efficacy of two-dimensional shear wave elastography (2D-SWE) for the diagnosis of pancreatic mass lesions. This ethics committee-approved cross-sectional study included 52 patients with histologically-proven pancreatic tumors (pancreatic ductal adenocarcinoma (PDAC), 36; tumor-forming pancreatitis (TFP), 15; neuroendocrine tumor, 1) and 33 control subjects. The 2D-SWE was performed for the tumor/non-tumor tissues, and SWE-mapping patterns and propagation quality were assessed. Three mapping patterns were detected based on the size and distribution of the coloring areas. Pattern A (whole coloring) was detected in all non-tumor tissues and TFP, whereas pattern C (multiple small coloring spots) was detected in PDAC only. Pattern B (partial coloring with smaller spots) was detected in other lesions. The specificity and positive predictive value of pattern A for non-PDAC and those of pattern C for PDAC were 100%. The SWE value was higher in tumor lesions than in the non-tumor tissues (38.1 vs. 9.8 kPa; 2D-SWE may play a role as a novel diagnostic tool for PDAC to detect a specific mapping pattern with quantitative assessment.
Sections du résumé
BACKGROUND
BACKGROUND
To investigate the efficacy of two-dimensional shear wave elastography (2D-SWE) for the diagnosis of pancreatic mass lesions.
METHODS
METHODS
This ethics committee-approved cross-sectional study included 52 patients with histologically-proven pancreatic tumors (pancreatic ductal adenocarcinoma (PDAC), 36; tumor-forming pancreatitis (TFP), 15; neuroendocrine tumor, 1) and 33 control subjects. The 2D-SWE was performed for the tumor/non-tumor tissues, and SWE-mapping patterns and propagation quality were assessed.
RESULTS
RESULTS
Three mapping patterns were detected based on the size and distribution of the coloring areas. Pattern A (whole coloring) was detected in all non-tumor tissues and TFP, whereas pattern C (multiple small coloring spots) was detected in PDAC only. Pattern B (partial coloring with smaller spots) was detected in other lesions. The specificity and positive predictive value of pattern A for non-PDAC and those of pattern C for PDAC were 100%. The SWE value was higher in tumor lesions than in the non-tumor tissues (38.1 vs. 9.8 kPa;
CONCLUSIONS
CONCLUSIONS
2D-SWE may play a role as a novel diagnostic tool for PDAC to detect a specific mapping pattern with quantitative assessment.
Identifiants
pubmed: 33799777
pii: diagnostics11030498
doi: 10.3390/diagnostics11030498
pmc: PMC8001884
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Gastroenterol. 2011 Jun;46(6):843-53
pubmed: 21505859
Ann Surg Oncol. 2004 Jun;11(6):555-7
pubmed: 15150065
Surg Pathol Clin. 2016 Dec;9(4):547-560
pubmed: 27926359
World J Gastroenterol. 2009 Apr 7;15(13):1587-93
pubmed: 19340900
Am J Gastroenterol. 2018 Sep;113(9):1301
pubmed: 29910463
Endocr Pathol. 2014 Mar;25(1):65-79
pubmed: 24430597
Eur J Radiol. 2017 Jul;92:17-23
pubmed: 28624015
Dtsch Med Wochenschr. 1990 Sep 7;115(36):1339-47
pubmed: 2204522
Eur J Radiol. 2014 Apr;83(4):620-4
pubmed: 24445135
Endoscopy. 2011 Jul;43(7):596-603
pubmed: 21437851
Tumour Biol. 2014 Sep;35(9):8867-74
pubmed: 24891188
Gastrointest Endosc. 2012 Nov;76(5):953-61
pubmed: 22854060
Abdom Radiol (NY). 2018 Apr;43(4):800-807
pubmed: 29116341
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Clin Endocrinol Metab. 2010 Dec;95(12):5281-8
pubmed: 20881263
Acad Radiol. 2010 Jul;17(7):849-55
pubmed: 20540909
J Gastroenterol. 2012 Apr;47(4):427-32
pubmed: 22065162
Gastrointest Endosc. 2009 Dec;70(6):1101-8
pubmed: 19647248
Aliment Pharmacol Ther. 2018 Mar;47(5):621-630
pubmed: 29322599
Hepatology. 2018 Jan;67(1):260-272
pubmed: 28370257
Ultrasound Med Biol. 2015 May;41(5):1161-79
pubmed: 25800942
Pancreas. 2011 Apr;40(3):352-8
pubmed: 21412117
Pancreatology. 2018 Mar;18(2):176-183
pubmed: 29305088
Ultrasonography. 2014 Jan;33(1):26-33
pubmed: 24936492
Eur J Radiol. 2016 Dec;85(12):2211-2216
pubmed: 27842669
Clin Imaging. 2017 Mar - Apr;42:64-67
pubmed: 27886609
J Hepatobiliary Pancreat Sci. 2016 Sep;23(9):595-602
pubmed: 27440720
Semin Radiat Oncol. 2005 Oct;15(4):254-64
pubmed: 16183479
Diagn Interv Imaging. 2016 Dec;97(12):1205-1206
pubmed: 27912865
World J Gastroenterol. 2017 Aug 28;23(32):5962-5968
pubmed: 28932088
Gastrointest Endosc. 2012 Feb;75(2):319-31
pubmed: 22248600
Gastroenterology. 2010 Oct;139(4):1172-80
pubmed: 20600020
Am J Gastroenterol. 2006 Jan;101(1):139-47
pubmed: 16405547
Ultrasound Med Biol. 2019 Aug;45(8):2242-2247
pubmed: 31103347